Infections

All Conditions

Neoplasms

Blood and Lymph Conditions

Immune System Diseases

Symptoms and General Pathology

Rare Diseases

Lymphoma

Communicable Diseases

Epstein-Barr Virus Infections

Lymphoproliferative Disorders

Virus Diseases

Lymphatic Diseases

Immunoproliferative Disorders

Herpesviridae Infections

DNA Virus Infections

Tumor Virus Infections

Lymphosarcoma

Post-transplant Lymphoproliferative Disease

Subjects receive an autologous anti-EBV T-cell line or a T-cell line derived from the patient's allogeneic (stem cell transplant) donor.

Subjects receive a T-cell line from a matched or partially matched related donor.

Peptide-stimulated T cells 2 x 10\^7/m\^2

Group A

Peptide-stimulated T cells per dose-escalation protocol

Group B

Jean-Sebastien Delisle, MD,PhD

Stephanie Thiant

Jean-Sébastien Delisle, MD, PhD

Stéphanie Thiant, PhD

This study evaluates the safety and efficacy of EBV-specific T-cell lines to treat patients suffering from high EBV viral titers not responding to standard of care therapies and to treat EBV-related lymphoma. The study will recruit 6 patients to receive autologous T cells or a T cell line derived from the patient's allogeneic donor (in the case of stem cell transplant recipients), and 6 patients to receive a T-cell line prepared from a matched or partially matched related donor.

Epstein-Barr virus (EBV) is a member of the herpes virus family and infects up to 95% of individuals over their lifetime. Most initial infections occur in childhood and after a brief flu-like illness, the virus enters a phase of latency.

Patients who receive a bone marrow transplant or an organ transplant take medications drugs that weaken their immune systems. In these contexts, the virus can "reactivate" and cause very serious problems, such as lymphoma. For unknown reasons, people with a normal immune system can also develop lymphoma due to EBV.

The purpose of this study is to test the safety and efficacy of immune cells (T lymphocytes) that are specifically "taught" to recognize the virus-infected cells and to eliminate them. This "education" occurs is done over during a 2 weeks period (approximately), in the research laboratory. The cells are then transfused into the patient.

A Study of the Safety and Efficacy of EBV Specific T-cell Lines

A Phase I/II Open-label Study of the Safety and Efficacy of Epstein-Barr Virus Specific T-cell Lines for the Treatment of EBV Infection or EBV-related Lymphoproliferative Diseases

Complications: infusional toxicity, immune-related and other

As measured by PCR weekly until week 6, at 3 months, 6 months and 12 months

ELISpot on peripheral blood is assessed at the time points mentioned above

Incidence/severity of graft-versus-host disease, solid organ rejection episodes, relapse

Based on standardized assessments done weekly until week 6 and at 3, 6 and 12 months

As clinically indicated by the investigators and/or primary physician

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Study of the Safety and Efficacy of EBV Specific T-cell Lines	NCT02580539	Epstein-Barr Vi... Post-Transplant... Lymphoma	Group A Group B	18 Years -	Maisonneuve-Rosemont Hospital
A Study of the Safety and Efficacy of EBV Specific T-cell Lines	NCT02580539	Epstein-Barr Vi... Post-Transplant... Lymphoma	Group A Group B	18 Years -	Maisonneuve-Rosemont Hospital

Spots Global Cancer Trial Database for group b

Every month we try and update this database with for group b cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for group b

Every month we try and update this database with for group b cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for group b cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.